RxDoctor Payments Data

Lisa Lee, MD

Hematology & Oncology · Irvine, CANPI 1144583733

Payments from drug & device makers

$1,593,239in general payments, 2019–2025

Across 243 payments — averaging $6556.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$777K
  • Janssen Research & Development, LLC$429K
  • Regeneron$319K
  • Takeda Pharmaceuticals U.S.A., Inc.$64K
  • E.r. Squibb & Sons, L.L.C.$5K
  • AstraZeneca$133
  • plus $492 from 7 others
$2,310in research payments, 2019–2025

Across 4 payments — averaging $577.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$2K
  • Pfizer$660

What the payments were for

  • Consulting fees$4,67187%
  • Food & beverage$57911%
  • Education$1152%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,593,239 in reported general payments places this provider in the 90th percentile of 1,363 hematology & oncology providers in California.

See all hematology & oncology providers in California

Medicare billing

Part B allowed, 2024
$104,755
Medicare patients
237
Services billed
843

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide67$1,222,556
Lenalidomide73$948,851
PomalystPomalidomide16$265,317
VenclextaVenetoclax12$131,863
EliquisApixaban28$28,454
XareltoRivaroxaban13$19,537
Atovaquone12$12,928
Enoxaparin Sodium14$3,579
Acyclovir83$1,956
Hydroxyurea13$513
Dexamethasone19$333
Gabapentin22$297
Oxycodone Hcl15$177
Famotidine18$119
Pantoprazole Sodium14$116

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Pomalyst$4,671$265,31716 claims
PfizerEliquis$776,639$28,45428 claims
Johnson & JohnsonXarelto$99$19,53713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,363 hematology & oncology providers in California.

Other hematology & oncology in Irvine

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →